Loading...
Suppression of autophagy by BCR/ABL
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a “reservoir” o...
Na minha lista:
| Udgivet i: | Front Biosci (Schol Ed) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7405106/ https://ncbi.nlm.nih.gov/pubmed/22202070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2741/278 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|